PRA Health Sciences, Inc. (PRAH) EPS Estimated At $0.77; Virtus Investment Advisers Has Trimmed Its Amphenol New (APH) Stake

April 18, 2018 - By Stephen Andrade

PRA Health Sciences, Inc. (NASDAQ:PRAH) Logo

Analysts expect PRA Health Sciences, Inc. (NASDAQ:PRAH) to report $0.77 EPS on April, 25 after the close.They anticipate $0.17 EPS change or 28.33% from last quarter’s $0.6 EPS. PRAH’s profit would be $49.12 million giving it 28.77 P/E if the $0.77 EPS is correct. After having $1.04 EPS previously, PRA Health Sciences, Inc.’s analysts see -25.96% EPS growth. The stock increased 0.72% or $0.63 during the last trading session, reaching $88.61. About 287,588 shares traded. PRA Health Sciences, Inc. (NASDAQ:PRAH) has risen 35.01% since April 18, 2017 and is uptrending. It has outperformed by 23.46% the S&P500.

Virtus Investment Advisers Inc decreased Amphenol Corp New (APH) stake by 11.98% reported in 2017Q4 SEC filing. Virtus Investment Advisers Inc sold 7,023 shares as Amphenol Corp New (APH)’s stock declined 2.89%. The Virtus Investment Advisers Inc holds 51,617 shares with $4.53 million value, down from 58,640 last quarter. Amphenol Corp New now has $26.52 billion valuation. The stock increased 0.40% or $0.35 during the last trading session, reaching $86.82. About 999,875 shares traded. Amphenol Corporation (NYSE:APH) has risen 20.58% since April 18, 2017 and is uptrending. It has outperformed by 9.03% the S&P500.

PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company has market cap of $5.65 billion. The firm offers integrated services, such as data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. It has a 67.13 P/E ratio. It also provides product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Among 15 analysts covering PRA Health Sciences (NASDAQ:PRAH), 10 have Buy rating, 0 Sell and 5 Hold. Therefore 67% are positive. PRA Health Sciences had 42 analyst reports since July 22, 2015 according to SRatingsIntel. The stock of PRA Health Sciences, Inc. (NASDAQ:PRAH) earned “Buy” rating by SunTrust on Monday, February 26. Jefferies maintained the shares of PRAH in report on Thursday, June 1 with “Buy” rating. The firm earned “Outperform” rating on Thursday, October 26 by Credit Suisse. On Monday, October 16 the stock rating was maintained by KeyBanc Capital Markets with “Buy”. Jefferies maintained the stock with “Buy” rating in Friday, October 27 report. On Thursday, November 30 the stock rating was maintained by Robert W. Baird with “Buy”. Citigroup maintained the shares of PRAH in report on Thursday, September 22 with “Buy” rating. On Thursday, February 22 the stock rating was maintained by Credit Suisse with “Outperform”. Citigroup upgraded the shares of PRAH in report on Wednesday, May 4 to “Buy” rating. The company was maintained on Thursday, October 26 by Robert W. Baird.

Among 11 analysts covering Amphenol (NYSE:APH), 5 have Buy rating, 0 Sell and 6 Hold. Therefore 45% are positive. Amphenol had 46 analyst reports since July 23, 2015 according to SRatingsIntel. RBC Capital Markets maintained it with “Buy” rating and $96.0 target in Wednesday, January 3 report. The rating was maintained by Morgan Stanley with “Equal-Weight” on Thursday, January 25. The firm has “Hold” rating by Stifel Nicolaus given on Wednesday, October 4. The stock has “Buy” rating by RBC Capital Markets on Monday, January 15. The company was maintained on Friday, September 15 by Cowen & Co. The rating was maintained by Morgan Stanley with “Equal-Weight” on Wednesday, December 13. The stock has “Top Pick” rating by RBC Capital Markets on Thursday, July 23. On Thursday, October 5 the stock rating was maintained by Deutsche Bank with “Buy”. The firm has “Hold” rating by Stifel Nicolaus given on Wednesday, September 27. Goldman Sachs upgraded the shares of APH in report on Tuesday, September 20 to “Buy” rating.

Virtus Investment Advisers Inc increased Prologis Inc (NYSE:PLD) stake by 1.24M shares to 1.36M valued at $7.67M in 2017Q4. It also upped Packaging Corp Amer (NYSE:PKG) stake by 14,074 shares and now owns 29,899 shares. Accenture Plc Ireland (NYSE:ACN) was raised too.

Since October 27, 2017, it had 0 insider buys, and 3 sales for $27.46 million activity. On Monday, October 30 NORWITT RICHARD ADAM sold $18.94 million worth of Amphenol Corporation (NYSE:APH) or 220,000 shares. $920,699 worth of stock was sold by D’AMICO LANCE E on Friday, February 2. Shares for $7.60M were sold by Gavelle Jean-Luc on Friday, October 27.

Amphenol Corporation (NYSE:APH) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: